Prevention of gastrointestinal complications by infusion pump in patients receiving enteral nutrition

Prevention of gastrointestinal complications by infusion pump in patients receiving enteral nutrition - Prevention of gastrointestinal complications by infusion pump in patients receiving enteral nutrition

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005609

Enrollment

Registered

2011-05-16

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inpatients receiving enteral nutrition via nasogastric tube, gastric fistula, or intestinal fistula

Interventions

Nutrition pump group Naturally dropped group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients aged from 20 to 90 years receiving enteral nutrition via nasogastric tube, gastric fistula, or intestinal fistula

Exclusion criteria

Exclusion criteria: 1. CD toxin positive 2.Patient with diarrhea by antibiotic or other medicines such as laxative 3.Patient taking: The semisolid preparation, K2-S, K-LEC, enteral nutrition containing more than 1.7 g/100 kcal of dietary fiber or 1 kcal/mL of calories. 4.Patient with impaired gastrointestinal absorption due to diseases (short bowel syndrome and inflammatory bowel disease) 5.Patient with impaired gastrointestinal motility due to disease 6.Patient with aspiration pneumonia 7. Severely ill patient with multiple (>2) organ failure 8.Patient with severe diarrhea 9.Patient with fatty diarrhea 10.Patient with lactose intolerance 11.Patient not recommended to be registered by physician

Design outcomes

Primary

Measure	Time frame
[BLOOD] labo data (on the registration, two weeks after, and at the end of the study) Blood chemistry: TP, ALB, BUN, CRE, CHE, T-CHO, TG, Na, Cl, K, GLU General blood count: WBC, RBC, Hb, Ht, SEG, LYMPH [URINE] labo data (on the registration, two weeks after, and at the end of the study) Specific gravity [OBSERVATION] items Defecation situation (with Bristol scale) Weight and frequency of defecation	—

Measure

Time frame

[BLOOD] labo data (on the registration, two weeks after, and at the end of the study) Blood chemistry: TP, ALB, BUN, CRE, CHE, T-CHO, TG, Na, Cl, K, GLU General blood count: WBC, RBC, Hb, Ht, SEG, LYMPH [URINE] labo data (on the registration, two weeks after, and at the end of the study) Specific gravity [OBSERVATION] items Defecation situation (with Bristol scale) Weight and frequency of defecation

—

Secondary

Measure	Time frame
Frequency of abdominal pain, nausea, and vomiting Presence of pressure ulcers, the presence of diaper rash, body weight, catheter problems, and choking	—

Countries

Japan

Contacts

Public ContactYuko Okuyama

Toho University Ohashi Medical Center Pharmaceutical department

ph-youka@oha.toho-u.ac.jp03-3468-1251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026